Thirdly, and perhaps most importantly, the telemedicine components that would be most crucial to improving adherent need to be better understood, so that the most efficient system can be designed. The current study used self-reported information and was focused on motivating patients to use CPAP. However, current technology can monitor CPAP pressures, leaks and objective compliance and send this information to the practitioner on a daily basis. Could early intervention using this information improve CPAP adherence even more? Alternatively, is it the regular automated telephone follow-ups that are most important in motivating patients to use the device? Does the patient perception of being continuously monitored by their healthcare team (whether or not they actually are) serve as the main motivator for adherence?

Despite these caveats, we believe it likely that telemedicine will be integrated into the care of patients with OSA in the near future. The potential benefits in terms of monitoring, early intervention of problems, patient education, improving adherence and improving patient outcomes should outweigh technology costs. However, the most cost-efficient way to do this is yet to be determined.

**Competing interests** NA has received a research grant from Respironics Inc. MK has no competing interests.

**Provenance and peer review** Commissioned; not externally peer reviewed.

Published Online First 26 October 2010

*Thorax* 2010;65:1035–1036.

doi:10.1136/thx.2010.140897

---

**REFERENCES**


---

**BCG vaccination: 90 years on and still so much to learn …**

**Ajit Lalvani, Saranya Sridhar**

The history of vaccination against tuberculosis abounds with instances of scientific discovery and rediscovery. At the end of the 19th and beginning of the 20th century, following Robert Koch’s announcement of his discovery of *Mycobacterium tuberculosis* in 1882, scientists across the world, including Koch himself, set out to invent a vaccine against tuberculosis. In 1908 Leon Calmette, a bacteriologist, and Camille Guérin, a veterinarian at the Pasteur Institute, Lille began an experiment to devise a vaccine by attenuating a *Mycobacterium bovis* strain until it lost its virulence. Thirteen years and 230 passages later, they were able to show that the strain was protective in animal models and no longer caused disease which was subsequently discovered to be primarily due to the loss of the genes in the region of difference 1 (RD1) region of the *M. bovis* genome.1 That same year, an infant of the 19th and beginning of the 20th

---

**Tuberculosis Research Unit, Department of Respiratory Medicine, National Heart and Lung Institute, Imperial College London, London, UK**

**Correspondence to** Ajit Lalvani, Tuberculosis Research Unit, Department of Respiratory Medicine, National Heart and Lung Institute, Imperial College London, Norfolk Place, London W2 1PG, UK; a.lalvani@imperial.ac.uk

---

**REFERENCES**

1. Patanakul S, Thongraj P, Woraprasert S, et al. Long-term adherence even more using this information improve CPAP adherence even more? Alternatively, is it the regular automated telephone follow-ups that are most important in motivating patients to use the device? Does the patient perception of being continuously monitored by their healthcare team (whether or not they actually are) serve as the main motivator for adherence?

Despite these caveats, we believe it likely that telemedicine will be integrated into the care of patients with OSA in the near future. The potential benefits in terms of monitoring, early intervention of problems, patient education, improving adherence and improving patient outcomes should outweigh technology costs. However, the most cost-efficient way to do this is yet to be determined.

**Competing interests** NA has received a research grant from Respironics Inc. MK has no competing interests.

**Provenance and peer review** Commissioned; not externally peer reviewed.

Published Online First 26 October 2010

*Thorax* 2010;65:1035–1036.

doi:10.1136/thx.2010.140897

---

**REFERENCES**


---

**BCG vaccination: 90 years on and still so much to learn …**

**Ajit Lalvani, Saranya Sridhar**

The history of vaccination against tuberculosis abounds with instances of scientific discovery and rediscovery. At the end of the 19th and beginning of the 20th century, following Robert Koch’s announcement of his discovery of *Mycobacterium tuberculosis* in 1882, scientists across the world, including Koch himself, set out to invent a vaccine against tuberculosis. In 1908 Leon Calmette, a bacteriologist, and Camille Guérin, a veterinarian at the Pasteur Institute, Lille began an experiment to devise a vaccine by attenuating a *Mycobacterium bovis* strain until it lost its virulence. Thirteen years and 230 passages later, they were able to show that the strain was protective in animal models and no longer caused disease which was subsequently discovered to be primarily due to the loss of the genes in the region of difference 1 (RD1) region of the *M. bovis* genome.1 That same year, an infant tuberculosis contact was given the first dose of this live attenuated vaccine, *M. bovis Bacille Calmette-Guerin* (BCG). Now, with over 3 billion doses administered, BCG is the most widely used vaccine worldwide.

Since its first use 90 years ago, BCG has been recommended as a vaccine because of its partial protective effect against active tuberculosis and death, albeit with greater efficacy against disseminated and meningeal disease in children than pulmonary disease in adolescents and adults.2,3 This, taken together with autopsy studies suggesting BCG decreases the size of pulmonary tuberculous foci thereby limiting bacillary multiplication and spread4 and animal models where BCG vaccination reduces bacillary burden after *M. tuberculosis* challenge but does not protect against infection, led to the long-standing dogma that BCG protects against dissemination and disease but not against infection. It was only 5 years ago that the first report5 of the ability of BCG to protect against the acquisition of infection changed our thinking about how BCG acts. The finding that BCG can act at an early stage in the pathway from tuberculosis exposure to disease (figure 1) has since been corroborated in community-based contact investigations in adults and children in Hamburg6 and in two studies investigating school tuberculosis outbreaks in the UK,7 the latest of which is published in the current issue of *Thorax* (see page 1067).8 Investigating a point-source tuberculosis outbreak at a nursery school, Eriksen and colleagues found that BCG-vaccinated children were significantly less likely to be infected, as judged by interferon-gamma release-assay (IGRA) results, than unvaccinated children. Vaccine effectiveness against infection was estimated at 66% but, given the small size of the study, the CIs are sufficiently wide to overlap with the 58%7 and 24%5 reduction in RR observed in the previous larger studies. Collectively, these data strongly suggest that at least part of the protective effect of BCG is attributable to protection against infection, which has substantial
implications for the development and evaluation of new TB vaccines as well as the role of BCG in TB control programmes. Indeed Eriksen and colleagues discuss the case for a reconsideration of the threshold for BCG vaccination in regions with differing TB incidence rates. However, conclusions about the causal role of BCG in protection against infection must be treated cautiously given the non-randomised nature of the observational studies to date although, the cumulative evidence from the multiple epidemiologically distinct settings makes the case for the causal role of BCG increasingly compelling.

In this issue of Thorax we also learn about another hitherto unrecognised effect of BCG which appears to be its ability to aid treatment resolution in patients with active disease. Jeremiah and colleagues report results from a longitudinal study of 546 adult patients with generally high initial sputum bacillary loads undergoing treatment for pulmonary tuberculosis in Tanzania (see page 1072); 5.5% of sputum culture results failed to convert to negative after 2 months of treatment, a well-established marker of risk of relapse after treatment completion. On multivariate analysis, the absence of a BCG scar was associated with a highly significant three-fold increased risk of sputum culture conversion failure. Patients with the highest initial sputum bacillary loads had a fivefold increased risk of 2 month sputum conversion failure as expected, while HIV status, CD4 count and body mass index were not significantly associated with sputum conversion failure. These results hint at a possible role for BCG in aiding the clearance of a large bacillary load during treatment. Considering that BCG does not protect against development of pulmonary tuberculosis in high-burden settings, its association with the microbiological response to treatment is unexpected and surprising. However, it is possible that antitubercular antibiotics and the host immune response cooperate in some way to reduce the mycobacterial burden in vivo, but the contribution of the host immune response per se is difficult to ascertain alongside the potent effect of antituberculous treatment in drug-sensitive disease. However, the significant rates of spontaneous recovery by patients with tuberculosis in the pre-antibiotic era in sanatoria and recent animal model data suggests a significant role for the host response in microbiological cure. Thus, it is at least plausible that host immunity plays a role in spum bacillary clearance, but how this immunity is positively and durably modulated by BCG vaccination many years earlier is unknown. It is moreover perplexing that the presumably immunologically-mediated effects of BCG on the microbiological response to treatment could be so strong when HIV status and CD4 counts did not significantly influence sputum conversion rate. The paper by Jeremiah et al lacks information about the antibiotic susceptibilities of the infecting strains which are a major determinant of time to sputum smear and culture conversion but, given the reported low prevalence of multidrug-resistant tuberculosis in Tanzania, this is unlikely to have confounded the findings. This remarkable first report of the association of BCG vaccination with treatment resolution must be treated with caution until further studies corroborate this observation; nonetheless, the findings should encourage further research in a similar vein extended to children, extrapulmonary disease and drug-resistant organisms. Interestingly, this report has extended the evidence on the protective effects of BCG by identifying another much later point in the natural history of tuberculosis infection where BCG appears to act (figure 1).

As well as the increasing evidence that BCG affects several distinct points in the natural history of tuberculosis, mounting data attributes beneficial effects of BCG on diseases other than tuberculosis including leprosy, asthma, childhood pneumonia and all-cause infant mortality. Thus, while we have been using BCG for almost a century, it is only more recently that an epidemiological evidence base is progressively revealing the pleiotropic effects of BCG on tuberculosis and other major diseases. Despite this recent progress in recognising the multiple effects of BCG, its immunological mechanisms of action as well as the reasons for its failure consistently to prevent adult pulmonary tuberculosis remain unclear. This is a major drawback, given the crucial importance of such understanding for the design and evaluation of new and improved tuberculosis vaccines with greater protective efficacy. Moreover, there are no less than twelve experimental vaccine candidates in clinical trials, most of which are being evaluated for their ability to boost immune responses originally primed by BCG. The problem is that we still do not know which of the immune responses induced by BCG mediate or correlate with protection against tuberculosis infection or disease. Although polyfunctional CD4 and CD8 T cells specific for M tuberculosis antigens are increasingly viewed as potential correlates or mediators of protective immunity in vaccine trials and are induced by the new vaccines, BCG-specific polyfunctional T cells do not correlate with protection against tuberculosis.

A significant difficulty in interpreting the findings of both the papers published in this issue of Thorax and, indeed, all observational studies investigating the protective effects and underlying mechanisms of BCG is the reliance on scar formation as a surrogate marker for BCG vaccination. The dependence on scar formation to infer vaccine take is complicated by the high prevalence (20%–50%) of vaccine recipients unable to form

Figure 1 Schematic of the protective effects of BCG at different steps in the natural history of tuberculosis. Grey arrows represent effects of BCG discovered in the last 5 years while the black arrows represent effects historically known.
a scar\textsuperscript{22–24} and the impact of vaccination technique on scar development.\textsuperscript{16} Moreover, scar formation does not correlate with BCG-induced development of adaptive cellular immune responses.\textsuperscript{25, 26} This unresolved relationship between scar formation and BCG vaccination makes investigation of the true protective effect of the vaccine, independent of the scar, difficult to evaluate in an era where randomised trials of BCG versus placebo are unethical. The question is therefore whether the partial protection against the different stages in the path from tuberculosis exposure to disease conferred by BCG vaccination is mediated by immune responses that are independent of the response required for scarry or by immune responses that also cause the scar. A third possibility is that the scar formation response to intradermal BCG is a surrogate marker of individuals who have pre-existing inherent protective immunity to tuberculosis that is not induced by BCG vaccination. Longitudinal immunopneumonological studies with clinical end points that follow BCG-vaccinated individuals who do and who do not scar are necessary to disentangle the immunological relationship between the triad of vaccination, scar formation and protection. Notably, large clinical end point vaccine trials designed to boost BCG with new vaccines may present an opportunity to resolve this thorny issue and identify true vaccine-induced correlates of protective immunity.

Like a fine wine that only gets better with age, 90 years after its immunity, BCG vaccine-induced correlates of protective life can only be understood backwards, but it must be lived forwards’.

Competing interests AL is inventor for several patents underpinning T cell-based diagnosis. The ESAT-6/CFP-10 IFN-gamma ELISpot was commercialised by an Oxford University spin-out company (T-SPOT.TB, Oxford Immunotec Ltd, Abingdon, UK) in which Oxford University and AL have minority shares of equity and entitlement to royalties. SS has no conflict of interest.

Provenance and peer review Commissioned; not externally peer reviewed.

Published Online First 21 October 2010


REFERENCES